Phrixus Pharmaceuticals is developing Carmeseal™ (poloxamer 188 or P188) for
Duchenne muscular dystrophy and acute decompensated heart failure.


Phrixus Pharmaceuticals announces SMARTT/NHLBI award of regulatory affairs and initial pharmacology and toxicology services for Carmeseal-MD under development to treat respiratory and cardiac deficits in Duchenne muscular dystrophy

read more


Phrixus has concurrence with FDA on the following:

1600 Huron Parkway, Building 520, 2nd Floor, Ann Arbor, MI 48109 (734) 358-9015
thomas.collet (at)
Created by J&M Marketing Communications /